Detalles de la búsqueda
1.
Bifurcation PCI with a hybrid strategy with drug- eluting balloons versus a stepwise provisional two- stent strategy: Rationale and design of the hybrid DEB study.
Am Heart J
; 266: 168-175, 2023 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-37806333
2.
Angiography-derived physiology guidance vs usual care in an All-comers PCI population treated with the healing-targeted supreme stent and Ticagrelor monotherapy: PIONEER IV trial design.
Am Heart J
; 246: 32-43, 2022 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-34990582
3.
Three-year clinical outcomes of the absorb bioresorbable vascular scaffold compared to Xience everolimus-eluting stent in routine PCI in patients with diabetes mellitus-AIDA sub-study.
Catheter Cardiovasc Interv
; 98(4): 713-720, 2021 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-33118696
4.
Bioresorbable Scaffolds versus Metallic Stents in Routine PCI.
N Engl J Med
; 376(24): 2319-2328, 2017 06 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-28402237
5.
Clinical outcomes at 2 years of the Absorb bioresorbable vascular scaffold versus the Xience drug-eluting metallic stent in patients presenting with acute coronary syndrome versus stable coronary disease-AIDA trial substudy.
Catheter Cardiovasc Interv
; 95(1): 89-96, 2020 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30968559
6.
A sirolimus-eluting bioabsorbable polymer-coated stent (MiStent) versus an everolimus-eluting durable polymer stent (Xience) after percutaneous coronary intervention (DESSOLVE III): a randomised, single-blind, multicentre, non-inferiority, phase 3 trial.
Lancet
; 391(10119): 431-440, 2018 02 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-29203070
7.
Everolimus-eluting bioresorbable stent vs. durable polymer everolimus-eluting metallic stent in patients with ST-segment elevation myocardial infarction: results of the randomized ABSORB ST-segment elevation myocardial infarction-TROFI II trial.
Eur Heart J
; 37(3): 229-40, 2016 Jan 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-26405232
8.
Comparison of zotarolimus-eluting and everolimus-eluting coronary stents.
N Engl J Med
; 363(2): 136-46, 2010 Jul 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-20554978
9.
Safety and efficacy of everolimus- versus sirolimus-eluting stents: a systematic review and meta-analysis of 11 randomized trials.
Am Heart J
; 165(2): 241-50.e4, 2013 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-23351828
10.
Comparison of Supraflex Cruz 60 µm Versus Ultimaster Tansei 80 µm Stent Struts in High Bleeding Risk PCI Patients: Study design and Rational of Compare 60/80 HBR trial.
Am J Cardiol
; 206: 230-237, 2023 Nov 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37708755
11.
Sirolimus-eluting stents with ultrathin struts versus everolimus-eluting stents for patients undergoing percutaneous coronary intervention: final three-year results of the TALENT trial.
EuroIntervention
; 18(6): 492-502, 2022 Aug 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-35285804
12.
Long-term clinical outcomes of everolimus-eluting bioresorbable scaffolds versus everolimus-eluting stents: final five-year results of the AIDA randomised clinical trial.
EuroIntervention
; 17(16): 1340-1347, 2022 Mar 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-34483094
13.
Clopidogrel in noncarriers of CYP2C19 loss-of-function alleles versus ticagrelor in elderly patients with acute coronary syndrome: A pre-specified sub analysis from the POPular Genetics and POPular Age trials CYP2C19 alleles in elderly patients.
Int J Cardiol
; 334: 10-17, 2021 Jul 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33887342
14.
Final 3-Year Outcomes of MiStent Biodegradable Polymer Crystalline Sirolimus-Eluting Stent Versus Xience Permanent Polymer Everolimus-Eluting Stent: Insights From the DESSOLVE III All-Comers Randomized Trial.
Circ Cardiovasc Interv
; 13(6): e008737, 2020 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-32466676
15.
Outcomes of bioresorbable vascular scaffolds versus everolimus-eluting stents by coronary complexity: a sub-analysis of the AIDA trial.
EuroIntervention
; 16(11): e904-e912, 2020 12 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-31062692
16.
A paradox in sex-specific clinical outcomes after bioresorbable scaffold implantation: 2-year results from the AIDA trial.
Int J Cardiol
; 300: 93-98, 2020 02 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31511193
17.
The influence of implantation techniques on lesion oriented-outcomes in Absorb BVS and Xience EES lesions treated in routine clinical practice at complete three year follow-up: AIDA trial QCA substudy.
Int J Cardiovasc Imaging
; 36(4): 565-575, 2020 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-31898006
18.
The relationship of pre-procedural Dmax based sizing to lesion level outcomes in Absorb BVS and Xience EES treated patients in the AIDA trial.
Int J Cardiovasc Imaging
; 35(7): 1189-1198, 2019 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-30911857
19.
Efficacy and Safety of Stents in ST-Segment Elevation Myocardial Infarction.
J Am Coll Cardiol
; 74(21): 2572-2584, 2019 11 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-31753202
20.
Complete two-year follow-up with formal non-inferiority testing on primary outcomes of the AIDA trial comparing the Absorb bioresorbable scaffold with the XIENCE drug-eluting metallic stent in routine PCI.
EuroIntervention
; 14(4): e426-e433, 2018 Jul 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-29786537